Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

Rhea-AI Summary

Clene Inc. (Nasdaq: CLNN) will participate in Renmark Financial Communications’ Virtual Non-Deal Roadshow Series on January 18 and 23, 2023. The company invites investors and stakeholders to attend these free live events, featuring presentations from CEO Rob Etherington and CFO Morgan Brown, followed by a Q&A session. Registration is recommended as attendance may be limited, but replays will be available on the company's Investor website afterward. Clene focuses on developing treatments for neurodegenerative diseases.

Positive

• Participation in a virtual roadshow may enhance visibility to investors.
• Free live events provide an opportunity for stakeholder engagement.

Negative

• None.

SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on January 18 and January 23. The Company welcomes stakeholders, investors, and other interested parties to register and attend these free live events.

Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will deliver the latest investor presentation followed by a live Q&A session. Individuals can register by using the link below. As a reminder, registration for the live events may be limited but access to the replays will be posted to the Company’s Investor website within a few days of the events.

REGISTER HERE AND EVENT DETAILS:

January 18, 2023 – 2 pm E.T., https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-01-18-120000

January 23, 2023 – Noon E.T., https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-01-23-120000

To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About Clene

Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.

Forward-Looking Statements 

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Clene’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements represent our views as of the date of this document and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date.

Contacts:

Renmark Financial Communications Inc.
James R. Kautz: jkautz@renmarkfinancial.com
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com

Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310

Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856

FAQ

When is Clene's virtual roadshow scheduled?

Clene's virtual roadshow is scheduled for January 18 at 2 pm E.T. and January 23 at Noon E.T.

Who will present at Clene's virtual roadshow?

Rob Etherington, CEO, and Morgan Brown, CFO, will present at the virtual roadshow.

How can I register for Clene's virtual roadshow?

You can register for Clene's virtual roadshow through the links provided in their press release.

What is the focus of Clene as a biopharmaceutical company?

Clene focuses on revolutionizing the treatment of neurodegenerative diseases by addressing energetic failure.